We’re changing the game for researchers

Making it easier to find specimens from diverse patient populations and find even the most “difficult” biospecimens now that the world is your biobank.

Group 345

81%

of researchers limit research due to lack of biospecimens

Group 345

81%

of researchers limit research due to lack of biospecimens

Group 345

81%

of researchers limit research due to lack of biospecimens

Procuring Samples

Providing Specimens

Latest News and Events

Featured Resources

Vestibulum euismod convallis odio nec eleifend. Quisque vestibulum, quam quis suscipit ullamcorper, lacus augue elementum lorem, in vehicula augue est in leo. Aliquam id vestibulum dolor. In semper, augue vitae facilisis pellentesque, nisi mi volutpat ipsum, ac accumsan nisl ex vitae velit.
Sed tincidunt lacus rhoncus, ultricies arcu a, auctor lorem. Etiam ac ex sed orci tincidunt dictum. Fusce a accumsan dolor. Pellentesque quam metus,

In a module, you will find an option to enable schema support. Once you enable this option, FAQ schema will be automatically added to your page. In case you are using an external plugin to add schema you can keep it disabled.

The module follows Google guidelines and adds FAQ schema.

This is tab content. Click to edit this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

This is tab content. Click to edit this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Group 503

Christopher Ianelli, MD, PhD

Founder and Chief Executive Officer

Group 503

Christopher Ianelli, MD, PhD

Founder and Chief Executive Officer

Chris conceptualized and founded iSpecimen in response to the precision medicine movement and the growing demand for biospecimens by life science researchers. As CEO, he is responsible for the company’s growth, performance, and corporate direction. Under his leadership, iSpecimen has become a dominant player in research sample procurement, recently developing and launching the industry’s first and only true marketplace platform connecting researchers with healthcare providers and biorepositories.

Prior to launching iSpecimen, Chris served as Managing Director at Leerink Partners (formerly Leerink Swann), a leading healthcare and life science investment bank, where he managed the expansion and delivery of services and directed strategy to develop new healthcare data and information assets for the firm. At Leerink, Chris launched Health Insight Technologies, a healthcare informatics company that was spun out of the firm as Humedica and acquired by UnitedHealth Group in 2013.

Prior to Leerink, Chris was a co-founder and Managing Director of Boston Medical & Scientific Advisors, a healthcare investment research firm ultimately acquired by Leerink. He received both his Ph.D. in Immunology and his M.D. from Tufts University and completed his residency training, including a year as Chief Resident, in Pathology at Brigham & Women’s Hospital and Harvard Medical School.

Andrew Ross

Board Member

          Video Transcription

          Video Transcription

          Video Transcription

          Video Transcription

          Video Transcription

          Video Transcription

          ValidationTesting

          2019-01-01

          Heading 1

          I am timeline card content. You can change me anytime. Click here to edit this text.

          2020-01-01

          Heading 2

          I am timeline card content. You can change me anytime. Click here to edit this text.

          2021-01-01

          Heading 3

          I am timeline card content. You can change me anytime. Click here to edit this text.

          Info Box

          Enter description text here. Lorem ipsum dolor sit amet, consectetur adipiscing. Quo incidunt ullamco.

          Cash $9,790,732 $695,909
          Accounts receivable - unbilled 1,750,744 652,761
          Accounts receivable, net of allowance for doubtful accounts of $141,952 and $108,096 at September 30, 2021 and December 31, 2020, respectively 2,718,682 1,526,392
          Inventory - -
          Prepaid expenses and other current assets 459,321 417,929
          Tax credit receivable, current portion 179,376 179,376
          Total current assets 14,898,855 3,472,367
          Property and equipment, net 44,749 75,589
          Internally developed software, net 2,650,867 2,634,139
          Tax credit receivable, net of current portion - -
          Security deposits 27,601 27,601
          Total assets $17,622,072 $6,209,696
          Current liabilities
          Accounts payable $351,424 $1,792,432
          Accrued expenses 1,025,136 810,910
          Accrued interest 7,510 3,696,944
          Convertible notes payable, related parties, net of unamortized debt discount and debt issuance costs - 5,490,811
          Derivative liability for embedded conversion features on convertible notes payable - 2,373,000
          Bridge notes payable, net of debt issuance costs - 4,589,228
          Bridge notes payable, related parties - 1,905,000
          Note payable, current portion - 604,109
          Deferred revenue 718,723 873,254
          Total current liabilities 2,102,793 22,135,688
          Note payable, net of current portion - 178,899
          Term loan 3,428,380 -
          Total liabilities 5,531,173 22,314,587
          Commitments and contingencies
          Series B convertible preferred stock, $0.0001 par value, 3,200,000 shares authorized, 0 and 572,465 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively - 7,999,997
          Series A-1 convertible preferred stock, $0.0001 par value, 556,550 shares authorized, 0 and 100,365 issued and outstanding at September 30, 2021 and December 31, 2020, respectively - 561,041
          Series A convertible preferred stock, $0.0001 par value, 3,427,871 shares authorized, 0 and 618,182 issued and outstanding at September 30, 2021 and December 31, 2020, respectively - 2,612,038
          Total convertible preferred stock - 11,173,076
          Stockholders' equity (deficit)
          Common stock, $0.0001 par value, 200,000,000 shares authorized, 6,996,758 issued, and 6,965,758 outstanding at September 30, 2021, and 16,000,000 shares authorized, 967,213 issued and 936,213 outstanding at December 31, 2020 697 94
          Additional paid-in capital 48,059,389 1,779,698
          Treasury stock, 31,000 shares at September 30, 2021 and December 31, 2020, at cost (172) (172)
          Accumulated deficit (35,969,015) (29,057,587)
          Total stockholders' equity (deficit) 12,090,899 (27,277,967)
          Total liabilities, convertible preferred stock and stockholders' equity (deficit) $17,622,072 $6,209,696
          2021 2020 2021 2020
          Revenue $2,718,534 $2,250,147 $8,586,217 $5,466,375
          Operating expenses:
          Cost of revenue 913,833 903,862 4,026,680 2,032,111
          Technology 543,581 413,381 1,315,331 1,131,695
          Sales and marketing 513,107 506,641 1,690,085 1,305,897
          Supply development 171,595 133,007 383,864 395,200
          Fulfillment 399,145 241,785 955,516 642,140
          General and administrative 1,636,346 774,550 4,144,989 1,431,262
          Total operating expenses 4,177,607 2,973,226 12,516,465 6,938,305
          Loss from operations (1,459,073) (723,079) (3,930,248) (1,471,930)
          Other expense, net Interest expense (75,922) (469,477) (2,062,548) (1,517,697)
          Change in fair value of derivative liability on convertible notes (54,000) (271,000) (76,000)
          Change in fair value of derivative liability on bridge notes and bridge notes, related parties 1,582,700
          Gain (loss) on extinguishment of bridge notes and bridge notes, related parties (2,740,425)
          Loss on extinguishment of convertible notes and convertible notes, related parties (260,185)
          Gain on extinguishment of note payable 788,156
          Other expense, net (21,687) (21,756) 6,691
          Interest income 3,659 87 3,878 396
          Other expense, net (93,950) (523,390) (2,981,180) (1,586,610)
          Income (loss) before benefit from income taxes (1,553,023) (1,246,469) (6,911,428) (3,058,540)
          Benefit from income taxes
          Net income (loss) $ (1,553,023) $(1,246,469) $(6,911,428) $(3,058,540)
          Net income (loss) per share
          Basic and diluted $(0.22) $(1.33) $(2.17) $(3.27)
          Weighted average common shares outstanding
          Basic and diluted 6,960,330 936,213 3,190,060 936,213
          Company Contact Country
          Alfreds Futterkiste Maria Anders Germany
          Centro comercial Moctezuma Francisco Chang Mexico
          Ernst Handel Roland Mendel Austria
          Island Trading Helen Bennett UK
          Laughing Bacchus Winecellars Yoshi Tannamuri Canada
          Magazzini Alimentari Riuniti Giovanni Rovelli Italy